News & Media

    10/17/2017
    Charleston Laboratories, Inc. Resubmits NDA for CL-108 
    08/31/2017
    Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting 
    02/15/2017
    Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire 
    02/03/2017
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use 
    01/26/2017
    Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary 
    01/24/2017
    Charleston Laboratories, Inc. Expands Senior Management Team with Two Key Appointments in Core Business Areas of Medical & Commercialization 
    06/13/2016
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108 
    05/11/2016
    Charleston Laboratories, Inc. Announces Presentations at the Annual Scientific Meeting of the American Pain Society 
    01/20/2016
    Governor Scott Announces Charleston Laboratories, Inc. Expansion Will Create 25 New Jobs 
    01/20/2016
    The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion 
    10/29/2015
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints 
    08/20/2015
    Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board 
    08/03/2015
    Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston’s Second Product, CL-H1T 
    05/13/2015
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting 
    04/06/2015
    Charleston Laboratories, Inc. Completes Patient Enrollment in a Phase 3 
    03/12/2015
    Charleston Laboratories, Inc. & Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108 
    11/20/2014
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials on Charleston’s Lead Product, CL-108 
    10/09/2014
    Prescription for Success 
    09/09/2014
    Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs 
    08/07/2014
    Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US 
    05/08/2014
    Charleston Laboratories, Inc., Bolsters Senior Management Team 
    10/29/2013
    Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain 
    10/09/2013
    Charleston Laboratories, Inc. Announces Research Collaboration with Stanford University 
    07/23/2013
    Charleston Laboratories, Inc Successfully Completes Pre-IND Meeting on New Migraine Treatment 
    04/16/2013
    FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment 
    01/28/2013
    Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial 
    11/02/2010
    Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project Grant 
    05/18/2009
    Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108 
    02/12/2009
    Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire 
    02/02/2009
    Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ) 
    01/12/2009
    Charleston Labs begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108 
    11/08/2007
    Charleston completes successful Type B, Pre-IND meeting with FDA’s Division of Anesthesia, Analgesia and Rheumatology Products on November 8, 2007, held at FDA’s Silver Spring, Maryland offices.